التفاصيل البيبلوغرافية
| العنوان: |
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. |
| المؤلفون: |
Zhou, Zhiyuan, Li, Xiang, Chen, Changying, Li, Xin, Zhang, Lei, Li, Ling, Wang, Xinhua, Ma, Wang, Fu, Xiaorui, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Yan, Jiaqin, Chang, Yu, Lu, Lisha, Qin, Beibei, Li, Xiaoli, Wen, Jianguo, Zhang, Mingzhi |
| المصدر: |
Annals of Hematology; Nov2014, Vol. 93 Issue 11, p1889-1894, 6p |
| مصطلحات موضوعية: |
DRUG efficacy, COMBINATION drug therapy, CANCER chemotherapy, MULTIDRUG resistance, LYMPHOMAS, HEMATOLOGICAL oncology |
| مستخلص: |
The prognosis of extranodal nature killer (NK)/T cell lymphoma (ENKL) is dismal because of its aggressive course and multidrug resistance. Currently, for patients with relapsed/refractory ENKL, l-asparaginase-based regimens such as l-asparaginase, ifosfamide, methotrexate, etoposide, and dexamethasone (SMILE) or l-asparaginase, methotrexate, and dexamethasone (AspaMetDex) are recommended. We retrospectively investigated the efficacy and safety of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of 17 relapsed/refractory ENKL patients. Clinical data from these patients were collected and analyzed. The primary end point was overall response rate (ORR). All patients were subjected to 2 to 6 cycles of DDGP chemotherapy, and the median number of cycles of DDGP regimen administrated was four. The ORR was 88.2 % (15/17), with nine patients (52.9 %) achieved complete response (CR) and six patients (35.3 %) achieved partial response (PR). The median follow-up time was 17 months (range 2-28 months). The 1-year overall survival (OS) rate and 1-year progression-free survival (PFS) were 82.4 and 64.7 %, respectively. For those CR responders, the median PFS was 17 months. Grade 3/4 neutropenia occurred in nine patients (52.9 %) and grade 3/4 thrombocytopenia occurred in six patients (35.3 %). DDGP combination chemotherapy produces favorable outcomes in relapsed/refractory ENKL, and more attention should be paid to treatment-related myelosuppression. Further prospective trials are expected to define the efficacy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
